FDA Approves BESREMi for Essential Thrombocythemia
The treatment landscape for essential thrombocythemia has reached an important milestone. The U.S. Food and Drug Administration (FDA) has approved BESREMi® (ropeginterferon alfa-2b-njft) for the treatment of adults with essential thrombocythemia (ET). According to PharmaEssentia USA Corporation, the approval represents the first new FDA-approved treatment for essential thrombocythemia in nearly three decades.
The approval gives physicians and adults living with ET another treatment option and expands the use of BESREMi, which was already approved and marketed for adults with polycythemia vera (PV). The new indication applies to adults with essential thrombocythemia regardless of genotype or disease status, including newly diagnosed patients who have not previously received cytoreductive therapy.
What Is Essential Thrombocythemia?
Essential thrombocythemia is a rare blood disorder and a type of myeloproliferative neoplasm, or MPN. The condition occurs when the bone marrow produces too many platelets.
Platelets play an important role in blood clotting. However, an excessive platelet count can contribute to complications. People living with essential thrombocythemia may face an increased risk of blood clots, abnormal bleeding and an enlarged spleen. Genetic mutations, including mutations affecting the JAK2 gene, are commonly associated with ET.
Because ET is a chronic condition, disease management can continue for many years. Treatment decisions are generally focused on reducing disease-related risks, controlling blood counts and managing symptoms.
Why Is the BESREMi Approval Important?
The FDA approval is significant because people with essential thrombocythemia have had limited treatment innovation for many years. The approval introduces another approach to disease management, particularly for patients and physicians looking for treatment options beyond traditional approaches.
PharmaEssentia describes BESREMi as a long-acting interferon-based therapy designed to provide sustained disease management. Unlike treatments that primarily focus on controlling platelet counts and symptoms, BESREMi is designed to target disease-driving cells in the bone marrow while reducing elevated platelet counts and disease burden.
This distinction is important because essential thrombocythemia is more than simply an elevated platelet count. The disease originates in the bone marrow, where abnormal blood cell production occurs. A treatment approach designed to address the underlying disease biology may therefore provide an additional option for long-term disease management.
What Clinical Evidence Supported the Approval?
The FDA approval was supported by clinical data from the global Phase 3 SURPASS ET study. The study evaluated BESREMi in adults with essential thrombocythemia and demonstrated durable modified European Leukemia Net, or ELN, responses as well as durable hematologic control.
According to PharmaEssentia, the Phase 3 SURPASS ET study showed superior durable response rates for BESREMi compared with anagrelide and reported reduced thromboembolic events over 12 months of treatment.
The study is identified as NCT04285086 and was a multicentre, open-label, randomized, active-controlled Phase 3 study. The published study is also listed among the references accompanying the announcement.
Who Can Receive BESREMi for ET?
The new FDA indication is for adults with essential thrombocythemia. The approval applies regardless of genotype or disease status, and it includes newly diagnosed adults who have not previously received cytoreductive therapy.
BESREMi is already an established product for adults with polycythemia vera. With the new indication, ropeginterferon alfa-2b-njft is now FDA-approved and marketed as BESREMi for both polycythemia vera and essential thrombocythemia.
Patients should discuss their individual medical history, disease characteristics, previous treatments and potential risks with a qualified healthcare professional before considering BESREMi.
Important Safety Information
Although the FDA approval provides an additional treatment option, BESREMi is associated with important warnings and precautions.
The prescribing information warns that interferon alfa products may cause or aggravate serious, potentially life-threatening neuropsychiatric, autoimmune, ischemic and infectious disorders. Patients receiving treatment should be monitored through appropriate clinical and laboratory evaluations.
BESREMi is contraindicated in people with a history of severe depression, suicidal ideation or suicide attempt, hypersensitivity to interferons or inactive ingredients, moderate or severe hepatic impairment, active serious or untreated autoimmune disease, or a history of transplantation while receiving immunosuppressant agents.
The safety information also highlights several areas requiring monitoring. These include depression and suicide risk, endocrine toxicity, cardiovascular toxicity, reduced peripheral blood counts, hypersensitivity reactions, pancreatitis, colitis, pulmonary toxicity and ophthalmologic toxicity. Healthcare professionals are also advised to monitor triglycerides, liver function and kidney function during treatment.
For patients, this means that treatment with BESREMi involves ongoing medical supervision rather than simply taking a medication without follow-up. Blood counts, liver function, kidney function and other relevant health measures may need to be monitored during therapy.
What Could This Mean for the Future of ET Treatment?
The approval of BESREMi represents a potentially important development in the treatment of essential thrombocythemia. For a chronic blood cancer in which patients may require years of ongoing management, having another FDA-approved treatment can give physicians greater flexibility when developing individualized care plans.
The approval also reflects continuing research into treatments that may address aspects of the disease beyond platelet count control. The company reports that BESREMi is designed to target disease-driving cells in the bone marrow while helping reduce elevated platelet counts and disease burden.
BESREMi's approval for ET follows regulatory approvals in Japan and Taiwan and further expands PharmaEssentia's portfolio in myeloproliferative neoplasms. The company stated that BESREMi for ET was expected to be available in the United States immediately upon approval.
Final Thoughts
The FDA approval of BESREMi for adults with essential thrombocythemia marks a notable change in the ET treatment landscape. After nearly three decades without a new FDA-approved treatment for ET, patients and healthcare professionals now have an additional option to consider.
The approval is supported by Phase 3 clinical evidence demonstrating durable responses and hematologic control. At the same time, BESREMi carries important safety warnings and requires appropriate monitoring.
For anyone living with essential thrombocythemia, treatment decisions should be individualized. Patients should speak with their hematologist or other qualified healthcare professional to understand whether BESREMi is appropriate for their specific condition, medical history and treatment goals.
Sources
- PharmaEssentia USA Corporation. “FDA Approves PharmaEssentia’s BESREMi (ropeginterferon alfa-2b-njft) for Adults with Essential Thrombocythemia.” August 31, 2026.
- Mesa R, Gill H, Zhang L, et al. “Ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia (SURPASS ET).” Lancet Haematology. 2025;12(11):e862-e875.
- Reeves BN, El Chaer F, Foltz L, et al. “Ropeginterferon alfa-2b-njft treatment in essential thrombocythemia across different driver mutations: results from a North American, single-arm, multicentre study (EXCEED-ET).” Lancet Regional Health - Americas. 2026;61:101529.
- PharmaEssentia Corporation. “What is ET?” Piece Together ET.
Medical Disclaimer
This article is provided for general informational and educational purposes only. It is not intended to provide medical advice, diagnosis or treatment recommendations. Patients with essential thrombocythemia should consult their hematologist or healthcare provider before starting, stopping or changing any treatment. Always review the current FDA-approved prescribing information for complete indications, contraindications, warnings, precautions and other safety information.